NewsStocksAltria CEO says 'responsibility needs to be at the heart' of its FDA-regulated nicotine business — part of why it sued the regulator

Altria CEO says 'responsibility needs to be at the heart' of its FDA-regulated nicotine business — part of why it sued the regulator

Author: Fortune Crypto·

Key Takeaways

  • •Altria CEO Sal Mancuso said at the Fortune 500 Innovation Forum in Detroit that FDA regulation has slowed the growth of the company's On! nicotine pouch brand.
  • •Altria announced its Moving Beyond Smoking initiative in 2023 to shift toward smoke-free alternatives such as NJOY vapes and On! pouches, which compete with Philip Morris's Zyn.
  • •In September, Altria's subsidiaries Helix Innovations and NJOY sued the FDA, alleging the agency's PMTA review process has blocked newer nicotine products from reaching the market.
  • •A federal judge granted a joint request last month to pause the lawsuit while the FDA considers revisions to the PMTA pathway and new rules.
  • •Mancuso claimed reviews meant to take six months have stretched to six years, letting illicit foreign products, particularly from China, take market share and skirt U.S. safety standards.
Altria CEO says 'responsibility needs to be at the heart' of its FDA-regulated nicotine business — part of why it sued the regulator

As Big Tobacco companies pivot away from combustible cigarettes toward less harmful nicotine alternatives, they are encountering new friction in their relationships with regulators.

Sal Mancuso, chief executive of Altria Group — the owner of cigarette and cigar brands including Marlboro and Black & Mild — addressed that tension at the Fortune 500 Innovation Forum in Detroit on Monday. Competing in an industry regulated by the U.S. Food and Drug Administration, he said, brings both a heightened sense of responsibility toward consumers and hurdles in competing with other businesses in the space. Mancuso identified the company's On! nicotine pouch brand as a key innovation, but said regulation has slowed its growth.

The Marlboro maker announced its Moving Beyond Smoking initiative in 2023 as more consumers move away from cigarettes, shifting its focus to smoke-free alternatives such as NJOY vapes and On! nicotine pouches — products now competing with Philip Morris's Zyn.

"You can call us the underdog in the pouch category today, but our intention is to lead the pouch category over the long term," Mancuso told Fortune Executive Editorial Director Diane Brady. "When you think about what's maybe getting in the way, there's a couple of factors: One is just the misperception that nicotine is what causes harm from tobacco use. Most of the harm is from combustion, so clarifying that misperception is important. And then we are regulated by the FDA. When you're in the nicotine business, responsibility needs to be at the heart of everything you do."

In September, Altria — through its subsidiaries Helix Innovations and NJOY — sued the FDA, alleging the agency has blocked newer nicotine products from reaching the market through its review process, which the company is seeking to overhaul. Under the Premarket Tobacco Product Application (PMTA) pathway, the FDA is legally required to review new tobacco products before they reach the market and determine whether a product delivers an overall public health benefit within 180 days of an application's submission. Altria contends the FDA has missed that deadline, and that the regulator's red tape and bureaucracy have stalled newer On! products from reaching shelves while foreign competitors flood stores.

The FDA has said it would consider revisions to the PMTA and weigh new rules as the market continues to change. Last month, U.S. District Judge James Wesley Hendrix of the Northern District of Texas granted a joint request from the FDA and the plaintiffs to pause the litigation. That pause leaves Altria's challenge unresolved for now, even as the agency weighs changes to a review process that determines which nicotine products can legally reach U.S. shelves.

According to Mancuso, the lawsuit was driven by the need for enforcement against illicit products. Echoing the complaint, he said reviews that should take the FDA six months were taking six years in some cases — allowing illegal products, particularly from China, to not only take market share but also skirt standards that Mancuso believes the agency should maintain to protect consumer safety. He claimed competing overseas products are marketed in vape shops as made in the U.S.A. despite being mislabeled.

"Quite frankly, the regulations are broken," Mancuso said. "There's too much information. We still want a high standard, but it should be streamlined."

"Guidance is not durable," he added. "It can be torn up immediately. What we want is more rapid authorization, so that consumers have product choices that they can choose from."

Mancuso suggested the nicotine regulatory landscape in some ways resembles how cannabis is being introduced and regulated in U.S. markets, where the substance is legal in half of U.S. states but no federal standard exists, producing a "hodgepodge" of regulations.

"Regulations are hard for any business," Mancuso said. "At the very least, it should be an even playing field, not a playing field where bad actors are in a better position than responsible companies like ours."

How the dispute evolves from here turns on the questions Altria put in motion: whether the FDA follows through on revisions to the PMTA and the new rules it has said it will weigh, and whether the paused lawsuit resumes. Either thread bears on how quickly new smoke-free products — including the On! items Altria says have been stalled — can reach American consumers.

This story was originally featured on Fortune.com.